← PCSK9 inhibitors × cardiovascular events

SynthesisCardiovascular drugs and therapy2023

Effect of PCSK9 Monoclonal Antibody Versus Placebo/Ezetimibe on Atrial Fibrillation in Patients at High Cardiovascular Risk: A Meta-Analysis of 26 Randomized Controlled Trials.

Shuai Yang et al.PubMed ↗Publisher ↗

What the trial testedas reported · 95,635 people · 2023

Not counted

Reduced cardiovascular events

−25%−34% to −15%

Bigger than 6 in 10 for cardiovascular events

As reported

RR 0.75, 95% CI 0.66–0.85

Not counted

Reduced cardiovascular events

−8%−13% to −3%

Bigger than 1 in 10 for cardiovascular events

As reported

RR 0.92, 95% CI 0.87–0.97

Range includes no effect

No clear effect on cardiovascular events

−5%−15% to +7%

Bigger than 1 in 10 for cardiovascular events

As reported

RR 0.95, 95% CI 0.85–1.07

Range includes no effect

No clear effect on cardiovascular events

+1%−5% to +8%

Smaller than almost all for cardiovascular events

As reported

RR 1.01, 95% CI 0.95–1.08

Four numbers in the abstract

the abstract, start to end

… incidence of cerebrovascular events (RR 0.75; 95% CI 0.66-0.85; p < 0.0001) and new-onset hypertension (RR 0.92; 95% CI 0.87-0.97; p = 0.003), but not the risk of cardiovascular death (RR 0.95; 95% CI 0.85-1.07; p = 0.40) and new-onset diabetes mellitus (RR 1.01; 95% CI 0.95-1.08; p = 0.67).

← favours treatmentfavours comparator →
could be chance
Cardiovascular events
RR 0.750.66–0.85
Cardiovascular events
RR 0.920.87–0.97
Cardiovascular events
RR 0.950.85–1.07
Cardiovascular events
RR 1.010.95–1.08
PCSK9 inhibitorsCardiovascular events
1 / 3

9 papers cite it

2023
2024
2025
this paperpooled itcites it
Full record →Abstract, authors, funding and every citing paper · PMID 35511323